Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

10.25p
   
  • Change Today:
      0.25p
  • 52 Week High: 34.25
  • 52 Week Low: 9.51
  • Currency: UK Pounds
  • Shares Issued: 99.27m
  • Volume: 1,995,991
  • Market Cap: 10.17m
  • RiskGrade: 435

Valirx Overview

ValiRx accelerates the development of treatments in cancer and womens health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

1 Day Chart (02-02-2023)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 3.0  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Valirx Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 n/a (3.55) (237.50)p n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (4.83) (117.50)p n/a n/a n/a n/a 0.0%
31-Dec-19 n/a (2.72) (4,135.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (1.54) (3.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (1.68) (2.34)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Valirx Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 n/a (1.96) (2.67)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (2.02) (1.86)p n/a n/a n/a n/a 0.0%

Copyright © 2023 FactSet Research Systems Inc. All rights reserved.

Valirx Company Announcements

Result of GM, Issue of Equity 02-Feb-2023 12:45 RNS
Operational Update 31-Jan-2023 07:02 RNS
Holding(s) in Company 31-Jan-2023 07:00 RNS

Latest Valirx Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Valirx Market Data

Currency UK Pounds
Share Price 10.25p
Change Today 0.25p
% Change 2.50 %
52 Week High 34.25
52 Week Low 9.51
Volume 1,995,991
Shares Issued 99.27m
Market Cap 10.17m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
38.55% below the market average38.55% below the market average38.55% below the market average38.55% below the market average38.55% below the market average
10.34% below the sector average10.34% below the sector average10.34% below the sector average10.34% below the sector average10.34% below the sector average
Price Trend
72.73% below the market average72.73% below the market average72.73% below the market average72.73% below the market average72.73% below the market average
38.71% below the sector average38.71% below the sector average38.71% below the sector average38.71% below the sector average38.71% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Valirx Dividends

No dividends found

Trades for 02-Feb-2023

Time Volume / Share Price
17:06 121,703 @ 10.25p
16:21 39,473 @ 11.00p
16:19 101,105 @ 10.05p
16:18 15,385 @ 10.34p
16:14 5,000 @ 10.05p

Valirx Key Personnel

CFO Gerald Desler
CEO Suzanne Dilly

Top of Page